WAVE Life Sciences reported quarterly losses of 32 cents per share which missed the analyst consensus estimate of losses of 30 cents per share. The company reported quarterly sales of $7.608 million which missed the analyst consensus estimate of $11.130 million.

Silvergate Bank announced it would delay the filing of its annual report as it may face regulatory probes. This sent the crypto-friendly bank's stock plunging. Wave Financial Head of Protocol and Treasury Management Nauman Sheikh reacts, saying, "I'm ...

Wells Fargo lowered the firm’s price target on Wave Life Sciences (WVE) to $16 from $18 and keeps an Overweight rating on the shares. The firm is

A total of 3 analyst ratings have been received for WAVE Life Sciences, with the consensus rating being Buy. The average one-year price target stands at $20.67, suggesting a potential 162.31% upside.

Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025; enrollment complete in first single dose cohort Multi-dosing ongoing in 200 mg cohort of RestorAATion-2 clinical trial of WVE-006 in AATD with data expected in ...

In 2019, one of the first known cases of deepfake scamming occurred when the CEO of an energy firm based in the U.K. was scammed out of €220,000 (about $243,000 USD at the time) after receiving a deepfaked phone call from the head of the firm's parent company in Germany.

Wave Life Sciences Ltd., a biotechnology company focused on RNA medicines, announced it will host a live webcast and conference call on May 8, 2025, at 8:30 a.m. ET to discuss its first quarter 2025 financial results and provide business updates.

Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. I’ve seen firsthand inside the belly of our financial system. And I can tell you that it’s designed to take advantage of the little guy.

D-Wave Quantum has experienced significant volatility, driven by the "Trump-Elon trade" hype, but financial struggles persist, warranting a Consensus Hold rating. The Trump-Elon effect has fueled speculative momentum in quantum computing stocks, with D ...

As hospital and health systems enter a new financial disruption era led by rising costs, the rapid adoption of AI and coverage loss, healthcare leaders are bracing for unprecedented changes. Over the next few years,